Sinusitis is the most common primary care infection worldwide leading to a significant economic health burden. It is the inflammation of the nasal passage or the sinus. The recent, newer term being used to describe sinusitis is rhinosinusitis as sinusitis without the occurrence of rhinitis is rare.
Rhinosinusitis can be classified as follows:
- Acute rhinosinusitis: Sudden onset, lasting less than 4 weeks with complete resolution.
- Subacute rhinosinusitis: A continuum of acute rhinosinusitis but less than 12 weeks.
- Recurrent acute rhinosinusitis: Four or more episodes of acute, lasting at least 7 days each, in any 1-year period.
- Chronic rhinosinusitis: Signs of symptoms persist 12 weeks or longer.
Nearly all cases of rhinosinusitis can be resolved by symptomatic treatment using analgesics and antibiotics.
The epithelial cells in the sinusitis are characterized by production of PG which further create swelling response in the nasal cavity. Cells also secrete a huge amount of IL-6 and Il1- beta which are proinflammatory cytokines and create an inflammatory microenvironment around epithelial cells which is responsible for immune cell filtration, localized pain and allergic responses associated with them.
In the current study mentioned drug treatment decreased both PG and inflammatory cytokines. It was observed that Absogen was the product which mainly exerted the significant inhibitory response (Raging between 34% to 53 % reduction in secretions). The effect shown by Absogen was both time dependent and dose dependent, it was remarkably interesting to observe that effect was incredibly significant at 12 hrs only which can be utilized to use as acute relief in condition. On the other hand, the effect of Abronym was also dose and time dependent but not as significant when compared to Absogen. Absogen was able to decrease specifically the expression MUCAC5 which a mucosal inflammation marker where as the expression of Th1, Th2 and Th17 specific molecules was not significant to observe.
When mixed Abronym was able to potentiate the effect of Absogen with 4 to 7.9 %. The results of current study clearly makes Absogen as top contender to be developed as a drug to fight the inflammatory response during sinusitis and further research should be done to check the molecular mechanisms of the same.